Boehringer Ingelheim's Survodutide Trial for NASH/MASH with Cirrhosis Underway
Boehringer Ingelheim is conducting a trial to evaluate the efficacy of survodutide in adults with NASH or MASH and cirrhosis.
Asset / Drug
Drug and asset intelligence for Survodutide with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.